Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsThe phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.
The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
1.
Researchers identify a novel biomarker linked to renal cancer recurrence
2.
We Can Advance Our Patients' Healing by One Step With 1,000 Paper Cranes.
3.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
4.
FDA approves rivanetin as the first-line treatment for lung cancer.
5.
After cancer: Study explores caring-healing modalities for survivors
1.
Preventing Venous Thromboembolism During Hematologic Cancer Care
2.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
3.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
4.
Mastering Oncology RCM: Reducing Errors, Denials & Improving Billing Efficiency
5.
An Overview Of Daunorubicin: What Is It Used For And How Does It Work?
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Expert Perspectives on Hematology
2.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Navigating the Complexities of Ph Negative ALL - Part III
5.
How Advances in Cancer Research Are Improving Treatment Options
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge